Parent company Rhegen Biotech's lyophilized mRNA vaccine for herpes zoster (RH110) has initiated Phase II clinical trials.
#Rhegen Biotech's Lyophilized mRNA Vaccine for Herpes Zoster (RH110) Initiates Phase II Clinical Trials#
Recently, the lyophilized mRNA vaccine for herpes zoster, RH110, independently developed by Rhegen Biotech, has officially initiated Phase II clinical trials. This trial adopts a randomized, double-blind, controlled, and multi-center design, aiming to evaluate the immunogenicity and safety of RH110 in subjects aged 40 and above.
The RH110 vaccine is an injectable lyophilized preparation, designed to prevent herpes zoster caused by the varicella-zoster virus. In the completed Phase I clinical trials, RH110 demonstrated excellent safety and tolerability.
The primary objective of this Phase II study is to evaluate the immunogenicity of the lyophilized mRNA vaccine for herpes zoster (RH110) in healthy individuals aged 40 and above. The primary endpoint indicators include: the geometric mean titer (GMT) and seroconversion rates of anti-gE antigen-specific serum antibodies and anti-VZV antigen-specific serum antibodies on day 30 after the administration of the second vaccine dose.
News you may be interested in:
